Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

This study is testing a combination of chemotherapy plus two immune-boosting drugs — sintilimab (an immunotherapy) and bevacizumab (an anti-blood vessel growth drug) — as a treatment given before surgery for triple-negative breast cancer (TNBC), a type of breast cancer that lacks common hormone and protein receptors. Researchers want to see if this combination can shrink tumors before surgery. **You may be eligible if:** - You are a female aged 18 to 70 - You have been diagnosed with stage II or III triple-negative breast cancer (ER-negative, PR-negative, HER2-negative) - Your cancer is confirmed by biopsy - Your major organs are functioning adequately - You are willing to use effective contraception during and for at least 6 months after treatment **You may NOT be eligible if:** - Your cancer has spread to other parts of the body (stage IV) - You have inflammatory breast cancer - You have already received cancer treatment or radiation - You have serious heart problems, including heart failure or uncontrolled arrhythmia - You have active infections, HIV, or uncontrolled hepatitis B or C - You are pregnant or breastfeeding - You have had a severe immune-related reaction to prior immunotherapy Talk to your doctor to see if this trial is right for you.